NEW YORK ( TheStreet) -- CHANGE IN RATINGSTD Ameritrade ( AMTD) downgraded at Citigroup to Neutral from Buy, Citigroup said. Retail trading re-engagement risks re-ignite. Boeing ( BA) upgraded at Stifel from Hold to Buy, Stifel Nicolaus said. $80 price target. Aerospace cycle remains strong. Buckeye Technologies ( BKI) upgraded at UBS to Buy from Neutral, UBS said. $36 price target. Risks are higher, but sell off seems overdone. Cummins ( CMI) downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company is leveraged to a likely NAFTA truck inventory correction later this year. Facebook ( FB) rated new Underperform at Bernstein. $25 price target. Company will likely struggle to achieve sales growth targets. Huntington Bancshares ( HBAN) downgraded at FBR from Market Perform to Underperform, FBR Capital Markets said. $6 price target. Company is leveraged to lower interest rates. HealthSouth ( HLS) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Valuation call. KAR Auction ( KAR) upgraded at Baird to Outperform, Robert Baird said. Valuation call, based on a $21 price target. NY Community Bancorp ( NYB) downgraded at FBR. NYB was downgraded from Outperform to Market Perform, FBR Capital Markets said. $13.50 price target. Estimates also cut, given lower expected net interest margin. PG&E ( PCG) rated new Equal-weight at Morgan Stanley. $47 price target. Risk/reward is neutral at cuirrent levels. Pioneer Natural ( PXD) upgraded at Societe Generale from Sell to Hold, Societe Generale said. Valuation call, based on a $92 price target. Regions Financial ( RF) downgraded at Morgan Stanley from Buy to Hold, Morgan Stanley said. $6.50 price target. Company is leveraged to slower macro growth and lower interest rates. Charles Schwab ( SCHW) downgraded at Citigroup to Neutral from Buy, Citigroup said. Retail trading re-engagement risks re-ignite. Zions Bancorporation ( ZION) downgraded at FBR from Outperform to Market Perform, FBR Capital Markets said. $21 price target. Company needs to cut costs, to cope with the lower interest rate environment.
STOCK COMMENTS / EPS CHANGES
Express Scripts ( ESRX) numbers lowered at BMO through 2013, BMO Capital said. Company is facing higher debt costs, following the Medco merger. Market Perform rating and new $50 price target.